BNR (Burning Rock Biotech) Additional Paid-In Capital : $687.06 Mil(As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Burning Rock Biotech Additional Paid-In Capital?

Burning Rock Biotech's quarterly additional paid-in capital increased from Jun. 2024 ($687.39 Mil) to Sep. 2024 ($706.18 Mil) but then stayed the same from Sep. 2024 ($706.18 Mil) to Dec. 2024 ($687.06 Mil).

Burning Rock Biotech's annual additional paid-in capital increased from Dec. 2022 ($657.34 Mil) to Dec. 2023 ($679.16 Mil) and increased from Dec. 2023 ($679.16 Mil) to Dec. 2024 ($687.06 Mil).

Burning Rock Biotech Additional Paid-In Capital Historical Data

The historical data trend for Burning Rock Biotech's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burning Rock Biotech Additional Paid-In Capital Chart

Burning Rock Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

612.70

672.12

657.34

679.16

687.06

Burning Rock Biotech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Additional Paid-In Capital	Get a 7-Day Free Trial															679.16	683.01	687.39	706.18	687.06

Burning Rock Biotech Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Burning Rock Biotech Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Burning Rock Biotech's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Burning Rock Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Burning Rock Biotech Ltd (NAS:BNR) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

6BU0:Germany

Address

No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005

Website

https://www.brbiotech.com

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.